These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19930611)

  • 1. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
    Talaulikar D; Shadbolt B; Dahlstrom JE; McDonald A
    J Hematol Oncol; 2009 Nov; 2():49. PubMed ID: 19930611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations.
    Talaulikar D; Dahlstrom JE
    Pathology; 2009; 41(3):214-22. PubMed ID: 19291532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision of histological bone marrow staging in follicular lymphoma and diffuse large B-cell lymphoma.
    Chen T; McDonald A; Shadbolt B; Talaulikar D
    Clin Invest Med; 2012 Dec; 35(6):E358-64. PubMed ID: 23217561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
    Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
    Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).
    Talaulikar D; Dahlstrom JE; Shadbolt B; Broomfield A; McDonald A
    J Histochem Cytochem; 2008 Oct; 56(10):893-900. PubMed ID: 18574254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective.
    Talaulikar D; Shadbolt B; Bell J; Khan K; Dahlstrom JE; McDonald A; Pidcock M; Broomfield A
    Histopathology; 2008 Feb; 52(3):340-7. PubMed ID: 18269585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
    Wen JJ; Liu ZB; Xu J; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.
    Tierens AM; Holte H; Warsame A; Ikonomou IM; Wang J; Chan WC; Delabie J
    Haematologica; 2010 Aug; 95(8):1334-41. PubMed ID: 20145271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Luo XL
    Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):771-5. PubMed ID: 16545182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.